Milestone Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 3/4
Milestone Pharmaceuticals VD är Joe Oliveto, utsedd i Mar 2017, har en mandatperiod på 9.17 år. totala årliga ersättningen är $ 2.12M, bestående av 30.6% lön 69.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.33% av företagets aktier, värda $ 669.37K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.1 år respektive 6.7 år.
Viktig information
Joe Oliveto
Verkställande direktör
US$2.1m
Total ersättning
| VD-lön i procent | 30.63% |
| Anställning som VD | 9.2yrs |
| Ägande av VD | 0.3% |
| Ledningens genomsnittliga anställningstid | 5.1yrs |
| Styrelsens genomsnittliga mandatperiod | 6.7yrs |
Senaste uppdateringar av ledningen
Recent updates
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular focused company centered on CARDAMYST, an etripamil nasal spray for on demand treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular-focused biopharmaceutical company with an FDA approved, self-administered intranasal therapy, CARDAMYST, for acute treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality
Summary Milestone Pharmaceuticals is downgraded to 'Sell' due to limited evidence supporting CARDAMYST's market adoption over generics. CARDAMYST's lack of statistically significant reduction in ER visits and high net price challenge its payer value proposition and peak share assumptions. My modeling, even with optimistic inputs, suggests MIST is overvalued with real downside risk, especially in a 'Bear' scenario where ROI is not achieved. Cash runway may be shorter than three years due to increased burn from CARDAMYST launch and AFib-RVR trial, raising dilution risk. Read the full article on Seeking AlphaDoes Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Key Insights Milestone Pharmaceuticals' Annual General Meeting to take place on 13th of June CEO Joe Oliveto's total...Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Milestone...What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
A look at the shareholders of Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) can tell us which group is most powerful...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$68m |
| Dec 31 2025 | US$2m | US$650k | -US$63m |
| Sep 30 2025 | n/a | n/a | -US$58m |
| Jun 30 2025 | n/a | n/a | -US$56m |
| Mar 31 2025 | n/a | n/a | -US$52m |
| Dec 31 2024 | US$854k | US$602k | -US$42m |
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$2m | US$602k | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$3m | US$584k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$4m | US$509k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$470k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$60m |
| Jun 30 2020 | n/a | n/a | -US$60m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$785k | US$458k | -US$55m |
Ersättning vs marknad: Joe s total kompensation ($USD 2.12M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 1.72M ).
Ersättning vs inkomst: Ersättningen för Joe har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Joe Oliveto (57 yo)
Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and had been its Director since July 2017. He serves as Executiv...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Executive Director | 9.2yrs | US$2.12m | 0.33% $ 669.4k | |
| CFO & Executive VP of Corporate Development | 6.7yrs | US$991.91k | 0.073% $ 149.8k | |
| Chief Medical Officer | 4.3yrs | US$1.02m | 0.083% $ 169.8k | |
| Founder | no data | inga uppgifter | inga uppgifter | |
| Chief Operating Officer | 5.9yrs | inga uppgifter | 0.037% $ 74.8k | |
| General Counsel & Chief Compliance Officer | less than a year | inga uppgifter | inga uppgifter | |
| Vice President of Marketing | 1.5yrs | inga uppgifter | inga uppgifter | |
| Vice President of Sales | 1.4yrs | inga uppgifter | inga uppgifter | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | 6.3yrs | inga uppgifter | inga uppgifter | |
| SVP of Regulatory Affairs and Quality Management | no data | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | 8.6yrs | US$645.72k | 0.15% $ 308.1k | |
| VP & Head of Medical Affairs | 3.8yrs | inga uppgifter | inga uppgifter |
Erfaren ledning: MIST s ledningsgrupp är erfaren och erfaren ( 5.1 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Executive Director | 8.8yrs | US$2.12m | 0.33% $ 669.4k | |
| Founder | 6.3yrs | inga uppgifter | inga uppgifter | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Observer | 8.8yrs | inga uppgifter | inga uppgifter | |
| Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Non-Executive Director | 3.2yrs | US$125.25k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Non-Executive Director | 7.1yrs | US$131.75k | 0.011% $ 22.5k | |
| Member of the Scientific Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Chairman of the Board | 5.6yrs | US$154.25k | 0.048% $ 97.5k |
Erfaren styrelse: MIST s styrelse anses vara erfaren ( 6.7 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 13:45 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Milestone Pharmaceuticals Inc. bevakas av 9 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Patrick Trucchio | H.C. Wainwright & Co. |
| Brandon Folkes | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |